More than 25 years after the initial derivation of human embryonic stem cell lines and 17 years following the discovery of human induced pluripotent stem cell lines, products derived from human pluripotent stem cells (hPSCs) are now progressing toward clinical application. Building on hPSCreg’s experience as a registry for hPSC lines, the human pluripotent stem cell registry (hPSCreg®) started a clinical study database to monitor the advancement of hPSC-based therapies (https://hpscreg.eu/clinical_studies). As of October 2025, this database contains 182 clinical studies, covering 14 clinical indications as categorized by ICD-10 chapters. We present the current status of these clinical trials and outline future challenges for the development of hPSC-based therapies.